Silence Therapeutics/$SLN
1D1W1MYTD1Y5YMAX
Capital at risk
About Silence Therapeutics
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
- Ticker
- $SLN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 88
- Headquarters
- London, United Kingdom
- Website
- www.silence-therapeutics.com
SLN Metrics
BasicAdvanced
$650M
-
-$1.27
1.44
-
Price and volume
Market cap
$650M
Beta
1.44
52-week high
$17.58
52-week low
$4.19
Average daily volume
784K
Financial strength
Current ratio
7.416
Quick ratio
6.398
Long term debt to equity
0
Total debt to equity
0.003
Profitability
EBITDA (TTM)
-63.942
Gross margin (TTM)
85.85%
Net profit margin (TTM)
-9,748.46%
Operating margin (TTM)
-10,475.61%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-29.65%
Return on equity (TTM)
-90.41%
Valuation
Price to revenue (TTM)
829.493
Price to book
13.26
Price to tangible book (TTM)
18.28
Price to free cash flow (TTM)
-12.07
Free cash flow yield (TTM)
-8.29%
Free cash flow per share (TTM)
-0.895
Growth
Revenue change (TTM)
-97.74%
Earnings per share change (TTM)
-24.59%
3-year revenue growth (CAGR)
-74.70%
3-year earnings per share growth (CAGR)
-6.65%
10-year earnings per share growth (CAGR)
11.90%
Bulls say / Bears say
Silence ended Q2 2026 with $72.1 million in cash and equivalents, which management expects will fund operations into 2028, reducing near-term dilution risk (SEC 10-Q)
Follow-up data from the Phase 1 SANRECO trial of Divesiran in polycythemia vera presented at EHA 2026 demonstrated durable efficacy and a potential best-in-class profile, bolstering the hematology franchise (MarketScreener)
The Zerlasiran (SLN360) program achieved Phase 3 readiness for reducing lipoprotein(a) and had its Phase 1 abstract accepted as a late-breaking oral presentation at EAS 2026, highlighting significant cardiovascular pipeline progress (Nasdaq)
AstraZeneca’s decision on March 4, 2026 not to pursue SLN312 beyond Phase 1 narrows Silence’s pipeline and removes a potential source of future milestone and royalty revenues (Nasdaq)
Silence recognized only $0.4 million in collaboration revenue in the first half of 2026 and achieved no milestone payments under its AstraZeneca agreement during that period, underscoring limited near-term partner cash inflows (SEC 10-Q)
The company reported a $14.1 million net cash outflow from operating activities in the six months ended June 30, 2026, highlighting ongoing operating losses and the need for additional financing despite a solid cash balance (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
SLN Financial Performance
Revenues and expenses
SLN Earnings Performance
Company profitability
Upcoming events
No upcoming events
SLN News
AllArticlesVideos
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Business Wire2 months ago
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Business Wire2 months ago
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
MarketBeat2 months ago
Funds containing SLN
AllUSDGBP
Fund name | Fund size | $SLN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.